Hsbc Global Res upgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY - Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports.
Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. cut Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a report on Thursday, August 29th. HSBC raised Reckitt Benckiser Group from a "hold" rating to a "buy" rating in a research note on Wednesday. Citigroup raised shares of Reckitt Benckiser Group to a "strong-buy" rating in a research note on Tuesday, October 1st. Sanford C. Bernstein cut shares of Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 4th. Finally, UBS Group raised shares of Reckitt Benckiser Group to a "strong-buy" rating in a research report on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy".
Check Out Our Latest Analysis on RBGLY
Reckitt Benckiser Group Trading Up 0.2 %
Shares of Reckitt Benckiser Group stock traded up $0.02 during trading on Wednesday, hitting $12.26. 229,072 shares of the company were exchanged, compared to its average volume of 861,540. The firm has a 50 day moving average price of $12.33 and a 200 day moving average price of $11.73. The company has a current ratio of 0.69, a quick ratio of 0.47 and a debt-to-equity ratio of 0.97. Reckitt Benckiser Group has a fifty-two week low of $10.24 and a fifty-two week high of $15.03.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
See Also
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
